Citadel Advisors’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Citadel Advisors’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32,668	Closed	-$621	–	15748
2023 Q1	$621	Buy	+32,668	New	+$3.15K	﹤0.01%	14454
2022 Q4	–	Sell	-75,414	Closed	-$13K	–	15746
2022 Q3	$13K	Sell	75,414 -100	-0.1%	-$15	﹤0.01%	12215
2022 Q2	$10K	Sell	75,514 -464	-0.6%	-$229	﹤0.01%	12593
2022 Q1	$60K	Sell	75,978 -3,233	-4%	-$2.26K	﹤0.01%	12689
2021 Q4	$48K	Sell	79,211 -197,086	-71%	-$200K	﹤0.01%	13278
2021 Q3	$262K	Buy	276,297 +37,655	+16%	+$39.2K	﹤0.01%	11374
2021 Q2	$334K	Buy	238,642 +11	+0%	+$10	﹤0.01%	11012
2021 Q1	$226K	Buy	+238,631	New	+$233K	﹤0.01%	11471

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Citadel Advisors's PEARW Position: Q2 2023 in Review

Citadel Advisors sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 32,668 shares — an estimated $621 sold.

Citadel Advisors first reported a position in PEARW in Q1 2021 and held it in 8 quarters. The position peaked at $334K in Q2 2021. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Citadel Advisors reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 32,668 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $621.
Citadel Advisors first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 8 quarters.
Citadel Advisors's Pear Therapeutics, Inc. Warrant position peaked at $334K in Q2 2021.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.